lncRNAs as Hallmarks for Individualized Treatment of Gastric Cancer

被引：4
作者：
Wu, Jing [1 ,2 ]
Xu, Shan [1 ,2 ]
Li, Wei [1 ,2 ]
Lu, Yuru [1 ,3 ]
Zhou, Yu [4 ,5 ]
Xie, Ming [1 ,6 ]
Luo, Yichen [1 ,2 ]
Cao, Yijing [1 ,7 ]
He, Yan [1 ,8 ]
Zeng, Tiebing [2 ,9 ,10 ]
Ling, Hui [1 ,2 ]
机构：
[1] Univ South China, Hengyang Med Coll, Canc Res Inst, Coll Hunan Prov,Key Lab Tumor Cellular & Mol Path, Hengyang 421001, Hunan, Peoples R China
[2] Hunan Prov Cooperat Innovat Ctr Mol Target New Dr, Hengyang 421001, Hunan, Peoples R China
[3] Univ South China, Hengyang Med Coll, Class 15, Clin Med 2018, Hengyang 421001, Hunan, Peoples R China
[4] Shaoyang Univ, Shaoyang 422000, Hunan, Peoples R China
[5] Shaoyang Univ, Affiliated Hosp 1, Shaoyang 422000, Hunan, Peoples R China
[6] Univ South China, Hengyang Med Coll, Clin Med Excellence Class 2018, Class 2, Hengyang 421001, Hunan, Peoples R China
[7] Univ South China, Affiliated Hosp 2, Dept Pathol, Hengyang 421001, Hunan, Peoples R China
[8] Longgang Cent Hosp, Dept Pathol, Shenzhen 518000, Guangdong, Peoples R China
[9] Univ South China, Inst Pathogen Biol, Hengyang 421001, Hunan, Peoples R China
[10] Univ South China, Key Lab Special Pathogen Prevent & Control Hunan, Hengyang 421001, Hunan, Peoples R China
来源：
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY | 2022年 / 22卷 / 08期
关键词：
Gastric cancer; lncRNAs; hallmarks; drug resistance; target; EMT; LONG NONCODING RNA; EPITHELIAL-MESENCHYMAL TRANSITION; PROMOTES CELL-PROLIFERATION; CISPLATIN RESISTANCE; MULTIDRUG-RESISTANCE; CHEMOTHERAPY RESISTANCE; MODULAR SCAFFOLD; FEEDBACK LOOP; HUMAN GENOME; EXPRESSION;
D O I：
10.2174/1871520621666210706113102
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Gastric cancer is a global cancer with a high mortality rate. A growing number of studies have found the abnormal expression of lncRNA (long noncoding RNA) in many tumors, which plays a role in promoting or inhibiting cancer. Similarly, lncRNA abnormal expression plays an essential biological function in gastric cancer. This article focuses on lncRNA involvement in the development of gastric cancer in terms of cell cycle disorder, apoptosis inhibition, metabolic remodeling, promotion of tumor inflammation, immune escape, induction of angiogenesis, and Epithelial Mesenchymal Transition (EMT). The involvement of lncRNA in the development of gastric cancer is related to drug resistance, such as cisplatin and multi-drug resistance. It can also be used as a potential marker for the diagnosis and prognosis of gastric cancer and a target for the treatment. With an in-depth understanding of the mechanism of lncRNA in gastric cancer, new ideas for personalized treatment of gastric cancer are expected.
引用
收藏
页码：1440 / 1457
页数：18
相关论文
共 160 条
[21]   LncRNA PVT1 Mediates Antiapoptosis and 5-Fluorouracil Resistance via Increasing Bcl2 Expression in Gastric Cancer [J].
Du, Peizhun ;
Hu, Cheng'en ;
Qin, Yunyun ;
Zhao, Jing ;
Patel, Rajan ;
Fu, Yan ;
Zhu, Mengqi ;
Zhang, Wenhong ;
Huang, Guangjian .
JOURNAL OF ONCOLOGY, 2019, 2019
[22]   Stem cell gene expression programs influence clinical outcome in human leukemia [J].
Eppert, Kolja ;
Takenaka, Katsuto ;
Lechman, Eric R. ;
Waldron, Levi ;
Nilsson, Bjoern ;
van Galen, Peter ;
Metzeler, Klaus H. ;
Poeppl, Armando ;
Ling, Vicki ;
Beyene, Joseph ;
Canty, Angelo J. ;
Danska, Jayne S. ;
Bohlander, Stefan K. ;
Buske, Christian ;
Minden, Mark D. ;
Golub, Todd R. ;
Jurisica, Igor ;
Ebert, Benjamin L. ;
Dick, John E. .
NATURE MEDICINE, 2011, 17 (09) :1086-U91
[23]   Upregulation of long noncoding RNA CCAT1-L promotes epithelial-mesenchymal transition in gastric adenocarcinoma [J].
Fang, Hua ;
Liu, Hui-Min ;
Wu, Wei-Hua ;
Liu, Han ;
Pan, Yong ;
Li, Wen-Jun .
ONCOTARGETS AND THERAPY, 2018, 11 :5647-5654
[24]   Long Non-Coding RNA (LncRNA) Urothelial Carcinoma Associated 1 (UCA1) Increases Multi-Drug Resistance of Gastric Cancer via Downregulating miR-27b [J].
Fang, Qun ;
Chen, XiaoYan ;
Zhi, XuTing .
MEDICAL SCIENCE MONITOR, 2016, 22 :3506-3513
[25]   Tissue-Specific Down-Regulation of the Long Non-Coding RNAs PCAT18 and LINC01133 in Gastric Cancer Development [J].
Foroughi, Kobra ;
Amini, Mohammad ;
Atashi, Amir ;
Mahmoodzadeh, Habibollah ;
Hamann, Ute ;
Manoochehri, Mehdi .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (12)
[26]   Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer Phase 2 Clinical KEYNOTE-059 Trial [J].
Fuchs, Charles S. ;
Doi, Toshihiko ;
Jang, Raymond W. ;
Muro, Kei ;
Satoh, Taroh ;
Machado, Manuela ;
Sun, Weijing ;
Jalal, Shadia I. ;
Shah, Manish A. ;
Metges, Jean-Phillipe ;
Garrido, Marcelo ;
Golan, Talia ;
Mandala, Mario ;
Wainberg, Zev A. ;
Catenacci, Daniel V. ;
Ohtsu, Atsushi ;
Shitara, Kohei ;
Geva, Ravit ;
Bleeker, Jonathan ;
Ko, Andrew H. ;
Ku, Geoffrey ;
Philip, Philip ;
Enzinger, Peter C. ;
Bang, Yung-Jue ;
Levitan, Diane ;
Wang, Jiangdian ;
Rosales, Minori ;
Dalal, Rita P. ;
Yoon, Harry H. .
JAMA ONCOLOGY, 2018, 4 (05)
[27]   The long non-coding RNA MALAT1 promotes ovarian cancer progression by regulating RBFOX2-mediated alternative splicing [J].
Gordon, Michael A. ;
Babbs, Beatrice ;
Cochrane, Dawn R. ;
Bitler, Benjamin G. ;
Richer, Jennifer K. .
MOLECULAR CARCINOGENESIS, 2019, 58 (02) :196-205
[28]   Long Noncoding RNA AFAP1-AS1 Promotes Cell Proliferation and Apoptosis of Gastric Cancer Cells via PTEN/p-AKT Pathway [J].
Guo, Jun-qiang ;
Li, Shi-jie ;
Guo, Guo-xiao .
DIGESTIVE DISEASES AND SCIENCES, 2017, 62 (08) :2004-2010
[29]   Circulating Exosomal Gastric Cancer-Associated Long Noncoding RNA1 as a Bioniarker for Early Detection and Monitoring Progression of Gastric Cancer A Multiphase Study [J].
Guo, Xin ;
Lv, Xiaohui ;
Ru, Yi ;
Zhou, Fuxing ;
Wang, Ning ;
Xi, Hongqing ;
Zhang, Kecheng ;
Li, Jiyang ;
Chang, Rongyan ;
Xie, Tianyu ;
Wang, Xinxin ;
Li, Baohai ;
Chen, Yong ;
Yang, Yanling ;
Chen, Lubin ;
Chen, Lin .
JAMA SURGERY, 2020, 155 (07) :572-579
[30]   PCAT-1 contributes to cisplatin resistance in gastric cancer through miR-128/ZEB1 axis [J].
Guo, Yinmou ;
Yue, Peiru ;
Wang, Yumei ;
Chen, Gongbin ;
Li, Yang .
BIOMEDICINE & PHARMACOTHERAPY, 2019, 118
12345678910